No Prescription |
 |
 | ||
|
Trusopt Eye Drops GB Generic Dorzolamide |
|
| ||
No Prescription » Prescription Drugs 16 » Trusopt Eye Drops GB Generic Dorzolamide Dorzolamide is used to treat high pressure inside the eye due to glaucoma (open angle-type) or other eye diseases (e.g. ocular hypertension). Lowering high pressure inside the eye helps to prevent blindness. This medication works by decreasing the amount of fluid within the eye. It belongs to a class of drugs known as carbonic anhydrase inhibitors. Buy Trusopt Eye Drops GB Generic Dorzolamide and other Prescription Drugs 16 products online at Medstore. Buy Online at Medstore - Click Here!
About Trusopt Eye Drops GB Generic Dorzolamide: Product Type: Prescription Drugs 16 Trusopt Eye Drops(GB) ( Generic Dorzolamide ) Product Origin: United Kingdom Trusopt Eye Drops (GB Generic Dorzolamide) GB Generic Dorzolamide 2% GB Generic Dorzolamide Trusopt Eye Drops
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
